We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+79.3%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.15B
AUM Growth
+$59.8M
Cap. Flow
-$271M
Cap. Flow %
-23.61%
Top 10 Hldgs %
64.68%
Holding
57
New
16
Increased
6
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$97.9M
2
NXTC icon
NextCure
NXTC
+$47.4M
3
TGTX icon
TG Therapeutics
TGTX
+$41.3M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$32.8M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$28.6M

Top Sells

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$72.3M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$69.8M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$40.9M
4
PEN icon
Penumbra
PEN
+$40.3M
5
NKTR icon
Nektar Therapeutics
NKTR
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 86.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
1
Iovance Biotherapeutics
IOVA
$1.82B
$139M 12.09%
5,015,175
-245,628
-5% -$5.59M
ZYME icon
2
Zymeworks
ZYME
$1.61B
$101M 8.8%
2,223,789
-242,955
-10% -$8.83M
PTCT icon
3
PTC Therapeutics
PTCT
$5.64B
$84.1M 7.32%
1,750,000
-250,000
-13% -$10.6M
AXSM icon
4
CALL
Axsome Therapeutics
AXSM
$11.2B
$75.2M 6.54%
727,200
+527,200
+264% +$21.3M
NXTC icon
5
NextCure
NXTC
$16.8M
$63.9M 5.56%
+94,549
New +$47.4M
TGTX icon
6
TG Therapeutics
TGTX
$7.96B
$60.3M 5.25%
+5,434,783
New +$41.3M
SAGE
7
DELISTED
Sage Therapeutics
SAGE
$57.5M 5%
+796,057
New +$97.9M
MNTA
8
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$55.1M 4.79%
2,790,400
+1,790,400
+179% +$28.6M
CNST
9
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$53.5M 4.66%
+1,135,122
New +$32.8M
ACAD icon
10
Acadia Pharmaceuticals
ACAD
$4.43B
$53.5M 4.66%
1,250,000
-940,742
-43% -$40.9M
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$53M 4.62%
1,000,000
-454,700
-31% -$20.7M
UTHR icon
12
United Therapeutics
UTHR
$25.8B
$47.7M 4.15%
541,179
+71,179
+15% +$6.26M
DERM
13
DELISTED
Dermira, Inc.
DERM
$39.7M 3.46%
2,621,333
– –
PRTA icon
14
Prothena Corp
PRTA
$425M
$33.3M 2.9%
2,100,941
+34,900
+2% +$374K
ABEO icon
15
Abeona Therapeutics
ABEO
$366M
$23.6M 2.05%
288,520
+159,096
+123% +$11.2M
ARVN icon
16
Arvinas
ARVN
$518M
$22.6M 1.97%
+550,000
New +$16.1M
ZGNX
17
DELISTED
Zogenix, Inc.
ZGNX
$21.9M 1.91%
420,000
-1,580,000
-79% -$72.3M
AUPH icon
18
CALL
Aurinia Pharmaceuticals
AUPH
$1.91B
$20.3M 1.76%
+1,000,000
New +$9.21M
TNDM icon
19
Tandem Diabetes Care
TNDM
$1.34B
$14.9M 1.3%
250,000
– –
GWPH
20
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$14.8M 1.29%
+141,683
New +$15.9M
ZGNX
21
CALL
DELISTED
Zogenix, Inc.
ZGNX
$13M 1.13%
250,000
– –
AXNX
22
DELISTED
Axonics, Inc. Common Stock
AXNX
$12.9M 1.13%
+466,507
New +$11.1M
KURA icon
23
Kura Oncology
KURA
$800M
$11.7M 1.02%
853,777
-2,232,276
-72% -$33.1M
TPST icon
24
Tempest Therapeutics
TPST
$13.7M
$11.7M 1.02%
8,871
+2,265
+34% +$3.19M
MTEM
25
DELISTED
Molecular Templates, Inc.
MTEM
$11.5M 1%
+55,000
New +$7.91M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Great Point Partners held 57 positions worth $1.15B, up 5.5% from $1.09B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Great Point Partners withdrew a net $271M in Q4 2019, closing 20 positions and reducing 11 holdings. Its most notable exit was Audentes Therapeutics, Inc, an estimated $69.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Sage Therapeutics worth $57.5M.

  • Great Point Partners's largest Q4 2019 buy was Sage Therapeutics: 796,057 shares worth $57.5M.
  • Great Point Partners added most to Momenta Pharmaceuticals, Inc. in Q4 2019, an estimated $28.6M increase.
  • Great Point Partners's biggest Q4 2019 reduction was Zogenix, Inc., cutting an estimated $72.3M.
  • Great Point Partners fully exited Audentes Therapeutics, Inc in Q4 2019, selling an estimated $69.8M.
  • Great Point Partners's ten largest holdings make up 65% of its $1.15B portfolio in Q4 2019.
  • Great Point Partners opened 16 new positions and closed 20 in Q4 2019.
  • Great Point Partners's portfolio value rose 5.5% quarter-over-quarter to $1.15B.

Based on Great Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.